Physician profile
Michelle Lerner
NPI 1326172321
$4,033.20
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,378 · 2022: $1,322 · 2023: $1,311 · 2024: $21.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $630.24 | 2021-2023 | Austedo, Uzedy, Austedo Xr |
| Abbvie INC. | $488.95 | 2021-2023 | |
| Lilly USA, LLC | $429.96 | 2021-2023 | Amyvid, Reyvow, Emgality |
| Neurocrine Biosciences, INC. | $314.62 | 2021-2023 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $220.81 | 2021 | |
| Almatica Pharma LLC | $217.00 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $171.76 | 2022 | |
| Pfizer INC. | $154.55 | 2023 | |
| Eisai INC. | $141.57 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.70 | 2021-2022 | |
| Alkermes, INC. | $119.99 | 2022 | |
| Sk Life Science, INC. | $119.98 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $119.52 | 2022-2024 | Ztlido |
| Allergan, INC. | $106.61 | 2021 | |
| Arbor Pharmaceuticals, INC. | $84.70 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $56.84 | 2021 | |
| Ucb, INC. | $56.05 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $53.08 | 2021-2023 | Nuedexta |
| Novo Nordisk INC | $43.07 | 2022 | |
| Sunovion Pharmaceuticals INC. | $41.66 | 2022 | |
| Biogen, INC. | $26.12 | 2023 | Tysabri, Vumerity |
| Celgene Corporation | $25.24 | 2023 | Zeposia |
| Argenx US, INC. | $24.00 | 2023 | Vyvgart |
| Xeris Pharmaceuticals, INC. | $23.49 | 2023 | Keveyis |
| Corium, LLC | $23.08 | 2022 | |
| Idorsia Pharmaceuticals US INC | $23.06 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $21.21 | 2023 | Aptiom |
| Avanir Pharmaceuticals, INC. | $21.10 | 2021 | |
| Harmony Biosciences LLC | $19.66 | 2022 | |
| Genentech USA, INC. | $18.37 | 2023 | Phesgo, Tecentriq |
| Currax Pharmaceuticals LLC | $17.86 | 2021 | |
| Indivior INC. | $15.31 | 2021 | |
| Merck Sharp & Dohme LLC | $15.28 | 2023 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $14.41 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.24 | 2021 | |
| Neos Therapeutics, LP | $12.32 | 2021 | |
| Bausch Health US, LLC | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.